Creatin-kinase elevation after accidental ingestion of almotriptan in an 18-month-old girl

E Castagno1, M Lupica, S Viola

  • 1Department of Pediatrics, University of Turin Regina Margherita Children's Hospital Turin, Italy - roberto.miniero@unicz.it.

Minerva Pediatrica
|March 11, 2014
PubMed

Insights

Accidental almotriptan ingestion in an 18-month-old led to elevated creatine kinase (CK) levels. Prompt hydration normalized CK, with no adverse effects observed in this pediatric migraine medication case.

Area of Science:

  • Pediatric Neurology
  • Clinical Toxicology

Background:

  • Limited data exists on almotriptan's safety and efficacy in young children with migraine.
  • Migraine treatment in early childhood requires careful consideration of potential adverse effects.

Observation:

  • An 18-month-old infant accidentally ingested 6.25 mg of almotriptan (0.48 mg/kg).
  • The child presented without specific symptoms, but investigations revealed elevated serum creatine kinase (CK) levels (527 IU/L).
  • Other biomarkers including transaminases, creatinine, aldolase, myoglobin, and troponin T remained within normal limits.

Findings:

  • Serum CK levels decreased significantly within 65 hours following parenteral rehydration with saline solution.
  • The infant experienced no adverse symptoms during hospitalization or follow-up.
  • This case highlights a potential biochemical change (elevated CK) following almotriptan overdose in a young child.

Implications:

  • This case suggests careful monitoring for muscle enzyme elevations after almotriptan ingestion in young children.
  • Further research is warranted to establish safe dosing and monitor for potential adverse effects of almotriptan in infants and children.
  • Understanding the biochemical impact of accidental overdose is crucial for pediatric migraine management guidelines.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
1.4K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
559
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229